Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Cabazitaxel for metastatic castration resistant prostate cancer (mCRPC): Interim safety and quality of life (QOL) data from the UK early access programme [Abstract]

Bahl, A. K., Masson, S., Malik, Z., Birtle, A., Sundar, S., Jones, R., James, N., Mason, Malcolm David, Kumar, S., Bottomley, D., Lydon, A., Chowdhury, S., Wylie, J. and De Bono, J. 2012. Cabazitaxel for metastatic castration resistant prostate cancer (mCRPC): Interim safety and quality of life (QOL) data from the UK early access programme [Abstract]. European Urology Supplements 11 (1) , e129. 10.1016/S1569-9056(12)60128-6

Full text not available from this repository.
Item Type: Article
Date Type: Publication
Status: Published
Schools: Medicine
Subjects: R Medicine > R Medicine (General)
R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
Additional Information: 27th Annual Congress of the European Association of Urology – Abstracts
Publisher: Elsevier
ISSN: 1569-9056
Last Modified: 04 Jun 2017 04:44
URI: http://orca-mwe.cf.ac.uk/id/eprint/43758

Actions (repository staff only)

Edit Item Edit Item